Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Funxional Therapeutics Ltd.

www.funxionaltherapeutics.com

Latest From Funxional Therapeutics Ltd.

Deals Shaping The Medical Industry, September 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Deals Of The Week: Merck/Chimerix, Merck/Yamasa, CoDa/Rusnano/Domain

AstraZeneca has done a good job of preparing investors for revenue declines due to its patent cliff, but Wall Street thinks the pharma will need to undertake significant M&A activity to remain viable.

BioPharmaceutical Deals

Boehringer Ingelheim pads respiratory pipeline with somatotaxin buy

Boehringer Ingelheim has acquired global rights to a Phase II respiratory compound and a broader inflammation development programme focused on a novel class of small molecule anti-inflammatory compounds from UK firm Funxional Therapeutics.

Dermatology Orthopedics

XOMA appoints Paul Rubin vice-president and CMO

XOMA, a company focused on the discovery and development of novel antibody therapeutics, has appointed Dr Paul Rubin vice-president and chief medical officer. Dr Rubin was previously CMO at Funxional Therapeutics. He will succeed Dr Patrick Scannon, who has been executive vice-president and CMO since 2009 and will now serve as executive vice-president and chief scientific officer.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Funxional Therapeutics Ltd.
  • Senior Management
  • Geoff Race, CEO
    David Grainger, PhD, CSO
  • Contact Info
  • Funxional Therapeutics Ltd.
    Phone: (0)1223 246602
    Homerton Business Centre, Purbeck Rd.
    Bldg. 14a
    Cambridge, CB2 8QL
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register